antibodi
protect
homolog
dengu
viru
denv
infect
precipit
sever
dengu
promot
heterotyp
viru
entri
via
receptor
immort
memori
b
cell
individu
primari
secondari
infect
analyz
antidenv
monoclon
antibodi
mab
thu
gener
mab
envelop
e
protein
domain
iii
diii
either
serotyp
specif
crossreact
potent
neutral
denv
infect
didiior
viral
membran
protein
prmreactiv
mab
neutral
poorli
show
broad
crossreact
four
denv
serotyp
mab
enhanc
infect
subneutr
concentr
three
mab
target
distinct
epitop
four
denv
serotyp
engin
prevent
bind
enhanc
infect
neutral
denv
vitro
vivo
postexposur
therapi
mous
model
lethal
denv
infect
find
reveal
unexpect
degre
crossreact
human
antibodi
denv
illustr
potenti
antibodybas
therapi
control
sever
dengu
dengu
viru
denv
mosquitoborn
flaviviru
respons
ten
million
human
case
dengu
annual
includ
hospit
death
gibbon
vaughn
econom
burden
rival
malaria
primari
infect
believ
provid
effect
durabl
possibl
lifelong
protect
reinfect
serotyp
shortterm
protect
serotyp
rothman
classic
epidemiolog
studi
suggest
immun
one
four
denv
serotyp
increas
diseas
sever
upon
subsequ
challeng
differ
serotyp
lead
case
sever
dengu
diseas
character
plasma
leakag
hemorrhag
manifest
halstead
poorli
neutral
crossreact
antibodi
rais
respons
previou
serotyp
believ
contribut
pathogenesi
sever
dengu
promot
viru
entri
via
receptor
infect
myeloid
cell
halstead
lead
antibodydepend
enhanc
ade
infect
role
antibodi
sever
dengu
support
epidemiolog
studi
show
infant
wane
level
matern
antibodi
age
month
vulner
sever
denv
diseas
halstead
et
al
nguyen
et
al
serum
infant
enhanc
denv
infect
vitro
chau
et
al
klik
et
al
difficulti
balanc
immun
four
serotyp
minim
incomplet
respons
risk
ade
major
hurdl
develop
tetraval
vaccin
denv
whitehead
et
al
kb
rna
genom
denv
encod
three
structur
protein
capsid
protein
c
membraneassoci
protein
prm
envelop
protein
e
seven
nonstructur
protein
e
protein
structur
conserv
among
flavivirus
consist
three
distinct
domain
domain
di
particip
conform
chang
requir
viral
entri
nucleocapsid
escap
endosom
compart
domain
ii
dii
contain
fusion
loop
domain
iii
diii
suggest
bind
cellular
receptor
bhardwaj
et
al
chin
et
al
chu
et
al
rey
et
al
partial
matur
virion
also
express
vari
level
prm
protein
surfac
normal
cleav
furinlik
cellular
proteas
gener
matur
virion
stadler
et
al
potent
neutral
antibodi
denv
flavivirus
west
nile
viru
wnv
bind
diii
shown
case
effect
passiv
prophylaxi
therapi
rodent
beasley
barrett
goncalvez
et
al
gromowski
et
al
kaufman
et
al
oliph
et
al
sanchez
et
al
shrestha
et
al
sukupolvipetti
et
al
diiireact
antibodi
produc
mice
immun
viru
boost
recombin
e
protein
larg
serotypespecif
neutral
genotyp
within
given
serotyp
shrestha
et
al
role
antibodi
didii
less
clear
tend
crossreact
less
potent
neutral
crill
chang
goncalvez
et
al
oliph
et
al
antibodi
prm
gener
poor
neutral
enhanc
activ
falconar
huang
et
al
although
recent
studi
suggest
antiprm
mab
augment
infect
poorli
infecti
immatur
virion
rodenhuiszybert
et
al
antibodi
secret
nonstructur
glycoprotein
absent
virion
express
cell
surfac
also
protect
infect
vivo
independ
mechan
chung
et
al
possibl
contribut
pathogenesi
falconar
lin
et
al
current
knowledg
human
antibodi
respons
denv
mostli
base
serolog
studi
studi
use
improv
method
memori
b
cell
immort
traggiai
et
al
combin
broad
screen
approach
isol
larg
panel
denvreact
mab
human
donor
mab
bound
diii
e
protein
potent
neutral
denv
infect
although
also
show
enhanc
activ
lower
concentr
contrast
mab
bound
didii
e
protein
prm
neutral
poorli
yet
potent
enhanc
infect
cell
surprisingli
human
diiispecif
mab
didiispecif
mab
isol
secondari
infect
show
broad
pattern
crossreact
four
denv
serotyp
base
improv
understand
function
humor
respons
denv
produc
cocktail
three
variant
recombin
mab
neutral
four
denv
serotyp
without
caus
immun
enhanc
vitro
vivo
blood
sampl
collect
donor
differ
time
point
diagnosi
either
primari
donor
donor
donor
secondari
donor
donor
denv
infect
igg
memori
b
cell
isol
frozen
pbmc
immort
ebv
cpg
multipl
replic
well
previous
describ
traggiai
et
al
cultur
supernat
collect
two
week
analyz
stain
fix
permeabil
mosquito
cell
infect
denv
elisa
use
recombin
e
protein
lysat
denvinfect
cell
tabl
frequenc
igg
memori
b
cell
reactiv
denvinfect
cell
calcul
number
posit
cultur
number
input
cell
correct
effici
b
cell
immort
high
donor
rang
igg
memori
b
cell
three
donor
screen
use
e
protein
frequenc
ereact
igg
memori
b
cell
rang
find
indic
denvimmun
donor
maintain
larg
pool
memori
b
cell
reactiv
denv
protein
even
sever
year
infect
e
protein
particular
diii
main
target
neutral
antiwnv
antibodi
mice
perform
larg
screen
gain
insight
domain
specif
crossreact
especif
antibodi
isol
donor
primari
donor
secondari
eighteen
antibodi
donor
bound
diii
serotyp
specif
crossreact
crossreact
four
denv
serotyp
case
donor
larg
fraction
ereact
antibodi
bound
diii
specif
diii
wherea
remain
crossreact
two
three
four
denv
serotyp
respect
taken
togeth
find
indic
human
antibodi
respons
diii
denv
e
protein
elicit
natur
infect
compris
serotyp
specif
well
broadli
crossreact
antibodi
order
better
character
human
antibodi
respons
denv
isol
b
cell
clone
sever
independ
cultur
character
denvreact
monoclon
antibodi
mab
either
denvreact
mab
bound
one
denv
serotyp
shown
stain
vero
cell
infect
see
exampl
figur
specif
crossreact
assess
use
bind
assay
elisa
recombin
e
protein
stain
yeast
display
didii
diii
western
blot
infect
cell
lysat
see
exampl
figur
mab
also
character
use
function
assay
neutral
enhanc
infect
denv
vaccin
strain
use
flow
cytometri
assay
vero
cell
respect
krau
et
al
littaua
et
al
see
exampl
figur
f
denvreact
mab
isol
map
diii
e
protein
serotypespecif
wherea
crossreact
two
three
even
four
denv
serotyp
tabl
five
serotypespecif
mab
three
potent
neutral
infect
vero
cell
either
vaccin
strain
ec
valu
low
ngml
rang
wherea
two
mab
show
decreas
potenc
suggest
may
repres
low
affin
antibodi
may
target
privat
epitop
within
crossreact
mab
two
potent
neutral
wherea
mab
potent
neutral
strikingli
crossreact
mab
neutral
infect
rang
concentr
observ
serotypespecif
mab
tabl
final
four
mab
bound
serotyp
elisa
two
neutral
albeit
low
potenc
serotyp
wherea
remain
mab
show
restrict
pattern
neutral
consist
known
stoichiometr
relationship
neutral
enhanc
diiispecif
mab
also
enhanc
infect
cell
given
rang
concentr
serotyp
specif
shown
neutral
assay
tabl
result
indic
possibl
isol
diiireact
human
mab
potent
neutral
infect
two
denv
serotyp
denvreact
mab
map
didii
e
protein
tabl
serotypespecif
crossreact
crossreact
four
denv
serotyp
compar
diiispecif
mab
didiispecif
mab
show
gener
lower
potenc
neutral
enhanc
infect
wide
rang
concentr
tabl
interest
wherea
diiireact
mab
isol
primari
infect
donor
mostli
serotypespecif
didiireact
mab
isol
secondari
infect
donor
neutral
enhanc
infect
four
denv
serotyp
find
suggest
broadli
crossreact
didiispecif
memori
b
cell
may
select
cours
secondari
denv
infect
broadli
reactiv
didiispecif
mab
analyz
reactiv
west
nile
viru
wnv
seven
mab
stain
yeast
cell
express
didii
wnv
e
protein
tabl
use
sitedirect
mutant
dii
previous
gener
crill
chang
oliph
et
al
local
bind
three
mab
fusion
loop
peptid
tip
dii
fourth
mab
residu
dimmer
interfac
dii
bind
three
crossreact
mab
affect
mutat
indic
map
didii
outsid
fusion
loop
region
final
mab
select
bind
denvinfect
cell
bind
recombin
e
protein
elisa
bound
e
protein
western
blot
figur
neutral
one
three
denv
serotyp
respect
wherea
neutral
denv
infect
highest
concentr
test
howev
mab
show
ade
activ
tabl
next
character
mab
stain
denvinfect
cell
recogn
e
protein
six
mab
react
band
western
blot
correspond
prm
indic
mous
antiprm
mab
use
control
falconar
figur
independ
verif
also
perform
crosscompetit
experi
found
antiprm
mab
inhibit
bind
suggest
may
recogn
overlap
epitop
wherea
compet
may
recogn
distinct
epitop
data
shown
surprisingli
five
mab
stain
band
correspond
eprm
protein
three
also
recogn
band
correspond
e
protein
reactiv
mab
prm
e
suggest
quaternari
epitop
share
site
heterodimer
prme
protein
similar
find
report
mous
antibodi
falconar
gould
et
al
puttikhunt
et
al
singl
except
mab
prmspecif
mab
broadli
crossreact
bound
cell
infect
four
denv
serotyp
tabl
prmreactiv
mab
enhanc
denv
infect
broad
rang
concentr
wherea
three
neutral
infect
low
potenc
tabl
thu
consist
recent
studi
dejnirattisai
et
al
prmspecif
mab
highli
crossreact
among
denv
serotyp
potent
promot
ade
eleven
mab
map
protein
determin
elisa
recombin
protein
western
blot
figur
data
shown
five
mab
crossreact
denv
serotyp
wherea
remain
two
mab
react
four
mab
tabl
final
one
mab
recogn
capsid
protein
tabl
figur
anoth
mab
assign
specif
protein
although
show
high
neutral
activ
lower
extent
tabl
mab
like
recogn
conformationallysensit
epitop
e
eg
hing
interfac
domain
oligom
observ
recent
two
human
mab
wnv
vogt
et
al
given
avail
human
mab
potent
neutral
denv
infect
set
develop
candid
antibodybas
therapeut
dengu
consist
cocktail
neutral
mab
ideal
cocktail
neutral
denv
serotyp
ii
target
least
two
nonoverlap
epitop
viru
order
minim
select
escap
mutant
iii
fail
enhanc
infect
therefor
select
two
mab
potent
complementari
neutral
activ
specif
diii
specif
didii
complement
select
didiispecif
mab
neutral
compar
effici
four
denv
serotyp
figur
crosscompetit
experi
consist
notion
target
epitop
recogn
three
mab
overlap
figur
thu
cocktail
expect
neutral
denv
serotyp
target
two
distinct
site
viru
select
neutral
mab
also
enhanc
infect
figur
gener
variant
leucin
residu
posit
domain
accord
imgt
uniqu
number
cdomain
substitut
alanin
residu
modif
also
known
lala
mutat
abolish
antibodi
bind
hessel
et
al
variant
unmodifi
recombin
mab
express
cell
purifi
mab
compar
capac
neutral
enhanc
infect
four
denv
serotyp
shown
figur
lala
variant
retain
neutral
activ
unmodifi
mab
complet
devoid
enhanc
activ
addit
lala
cocktail
even
low
concentr
ml
block
ade
induc
enhanc
prm
didii
mab
immun
serum
figur
determin
whether
combin
lala
mab
might
achiev
increas
neutral
use
variabl
ratio
approach
zwick
et
al
concentr
one
mab
vari
presenc
fix
amount
second
mab
ad
weakli
neutral
concentr
titrat
curv
first
mab
alon
combin
compar
ec
valu
shown
tabl
indic
twoto
fourfold
increas
neutral
potenc
consist
modest
addit
effect
taken
togeth
result
suggest
cocktail
three
lala
variant
mab
target
differ
epitop
viru
effici
neutral
denv
infect
avoid
actual
prevent
enhanc
denv
infect
vitro
assess
abil
lala
variant
neutral
denv
vivo
util
recentlydescrib
mous
model
denv
ade
subleth
infect
enhanc
passiv
transfer
antidenv
antibodi
lead
lethal
diseas
character
plasma
leakag
elev
serum
cytokin
thrombocytopenia
balsiti
et
al
zellweg
et
al
featur
associ
sever
dengu
human
unmodifi
lala
variant
mab
transfer
mice
hour
prior
subleth
infect
strain
wherea
mice
receiv
mous
mab
panflaviviru
e
didiispecif
develop
enhanc
lethal
infect
mice
receiv
lala
mab
variant
succumb
infect
figur
lala
p
lala
p
compar
show
sign
ill
contrast
one
except
mice
pretreat
unmodifi
mab
show
enhanc
lethal
denv
infect
wherea
mice
receiv
pb
alon
surviv
infect
figur
abil
unmodifi
mab
enhanc
denv
mice
affect
differ
interact
human
mab
murin
inde
chimer
mab
human
constant
region
hing
domain
replac
homolog
murin
constant
region
enhanc
denv
infect
compar
vitro
vivo
data
shown
determin
whether
surviv
associ
transfer
lala
variant
associ
reduc
viral
load
measur
viral
burden
serum
tissu
day
follow
antibodyenhanc
infect
viremia
tissu
viral
load
measur
liver
small
intestin
lymph
node
significantli
decreas
mice
receiv
either
lala
variant
compar
mice
receiv
parent
unmodifi
mab
figur
p
comparison
mab
variant
liver
sera
lymph
small
intestin
p
comparison
mab
variant
p
mab
variant
explor
whether
lala
variant
could
serv
possibl
therapi
follow
denv
infect
administ
lala
variant
unmodifi
mab
mice
hour
infect
enhanc
condit
hour
transfer
heterotyp
serum
balsiti
et
al
mice
receiv
either
lala
variant
surviv
normal
lethal
infect
wherea
mice
receiv
unmodifi
parent
mab
succumb
infect
mice
receiv
nonbind
isotyp
control
lala
mab
recogn
pb
figur
lala
p
lala
p
compar
lala
summari
engin
lala
mutat
strongli
neutral
human
mab
abrog
capac
ade
confer
protect
phenotyp
postexposur
therapi
mice
studi
analyz
memori
b
cell
repertoir
individu
recov
primari
secondari
denv
infect
character
larg
panel
mab
specif
structur
nonstructur
protein
denv
main
find
immun
donor
larg
repertoir
denvreact
memori
b
cell
even
year
infect
human
especif
well
prmspecif
mab
isol
donor
show
extens
crossreact
among
four
denv
serotyp
previou
studi
use
mous
mab
establish
diii
primari
target
potent
neutral
antibodi
flavivirus
includ
wnv
denv
beasley
barrett
gromowski
barrett
oliph
et
al
oliph
et
al
sanchez
et
al
sukupolvipetti
et
al
find
human
agre
observ
isol
diiispecif
mab
inde
potent
neutral
denv
infect
vero
cell
ec
valu
low
ngml
rang
howev
wherea
mab
produc
mice
boost
recombin
e
protein
could
neutral
genotyp
within
given
serotyp
shrestha
et
al
human
mab
diii
show
consider
breadth
mab
abl
neutral
three
even
four
denv
serotyp
didiispecif
mab
less
potent
viral
neutral
show
even
higher
degre
crossreact
strikingli
analysi
perform
larg
number
cultur
supernat
show
fraction
diiiand
didiicrossreact
antibodi
consider
higher
secondari
infect
instanc
supernat
contain
diiispecif
antibodi
donor
secondari
crossreact
two
three
four
denv
serotyp
wherea
didiispecif
mab
donor
secondari
crossreact
compar
ec
valu
four
denv
serotyp
within
especif
respons
rel
proport
didii
versu
diii
antibodi
show
consider
variabl
differ
donor
howev
overal
preval
didii
antibodi
consist
serolog
studi
wnv
denv
crill
et
al
lai
et
al
oliph
et
al
wahala
et
al
moreov
two
recent
studi
describ
recombin
antiwnv
antibodi
gener
phage
display
screen
scfv
v
h
v
l
molecul
gould
et
al
throsbi
et
al
observ
immunodomin
didii
mab
wnv
e
protein
unclear
reason
appear
diiispecif
antibodi
less
abund
human
repertoir
although
still
may
contribut
significantli
protect
crill
et
al
neutral
mab
isol
studi
mediat
ade
subneutr
concentr
wherea
especif
mab
prmspecif
mab
mediat
ade
lack
neutral
activ
previou
studi
report
isol
three
human
e
proteinspecif
mab
two
show
enhanc
neutral
activ
schieffelin
et
al
recent
screaton
cowork
show
prmspecif
mab
repres
major
compon
human
denvspecif
respons
mab
highli
crossreact
even
high
concentr
neutral
infect
potent
promot
ade
dejnirattisai
et
al
consist
data
prmspecif
mab
describ
present
studi
highli
crossreact
show
ade
activ
broad
rang
concentr
human
studi
togeth
previou
studi
mous
antiprm
mab
neutral
infect
weakli
potent
mediat
ade
falconar
henchal
et
al
huang
et
al
roehrig
et
al
suggest
potenti
role
class
antibodi
enhanc
denv
infect
human
recent
studi
infant
also
implic
antiprm
antibodi
suscept
infant
sever
dengu
chau
et
al
also
propos
antiprm
antibodi
could
enhanc
denv
propag
enhanc
infect
immatur
noninfecti
virion
rodenhuiszybert
et
al
howev
vast
major
human
experienc
secondari
denv
infect
develop
sever
lifethreaten
diseas
didiispecif
antibodi
less
frequent
highli
neutral
diiispecif
antibodi
like
protect
along
compon
innat
adapt
immun
system
develop
vaccin
denv
problemat
part
due
possibl
risk
elicit
suboptim
immun
respons
might
lead
ade
sever
diseas
infect
heterolog
virul
strain
absenc
effect
denv
vaccin
passiv
immunotherapi
neutral
antibodi
may
provid
altern
treatment
dengu
postexposur
prophylaxi
approach
current
pursu
treatment
sever
viral
diseas
respiratori
syncyti
viru
rsv
rabi
hepat
b
wnv
marasco
sui
human
antidenv
mab
obtain
mice
primat
engin
mutat
prevent
bind
fcr
develop
purpos
balsiti
et
al
goncalvez
et
al
fulli
human
mab
gener
natur
infect
repres
attract
altern
reduc
antigen
risk
autoreact
select
three
potent
human
neutral
mab
compon
cocktail
capabl
target
two
distinct
epitop
four
denv
serotyp
engin
two
leucin
alanin
mutat
region
prevent
bind
preserv
bind
neonat
fcrn
hessel
et
al
lala
variant
retain
neutral
activ
test
vitro
fail
enhanc
denv
infect
inhibit
enhanc
elicit
polyclon
immun
sera
appropri
concentr
intact
antibodi
test
vivo
mous
model
lethal
antibodyenhanc
vascular
leak
syndrom
lala
mab
protect
lethal
infect
induc
denvimmun
serum
postexposur
therapeut
even
though
effector
function
enhanc
protect
efficaci
antiflaviviru
antibodi
chung
et
al
mehlhop
et
al
oliph
et
al
schlesing
et
al
requir
highli
neutral
antibodi
thu
least
mice
even
ade
initi
time
window
neutral
antibodi
lack
abil
enhanc
infect
still
protect
lethal
diseas
result
foundat
investig
address
whether
antibodybas
therapeut
control
sever
denv
diseas
human
peripher
blood
sampl
obtain
donor
diagnos
denv
infect
studi
protocol
approv
scientif
ethic
committe
hospit
tropic
diseas
oxford
tropic
research
ethic
committe
provid
written
inform
consent
determin
primari
secondari
dengu
made
basi
acut
serolog
result
prnt
assay
late
convalesc
peripher
blood
mononuclear
cell
isol
cryopreserv
day
use
pbmc
thaw
igg
memori
b
cell
enrich
use
microbead
miltenyi
follow
cell
sort
describ
traggiai
et
al
cell
immort
cellswel
multipl
cultur
use
ebv
cpg
oligodeoxynucleotid
microsynth
irradi
allogen
pbmc
week
cultur
supernat
screen
presenc
denvspecif
mab
posit
cultur
clone
limit
dilut
vero
cell
infect
recov
donor
recov
donor
refer
strain
vaccin
strain
moi
lead
infect
cell
day
cell
harvest
fix
formaldehyd
sigma
permeabil
pb
fc
saponin
sigma
cell
incub
ice
b
cell
cultur
supernat
wash
stain
goat
antihuman
igg
jackson
immunoresearch
analyz
facsarray
bd
bioscienc
elisa
elisa
plate
coat
recombin
e
protein
rey
recombin
diii
donor
diii
simonelli
et
al
na
carbon
buffer
ph
wash
block
mab
ad
wash
mab
bound
reveal
use
goat
antihuman
igg
coupl
alkalin
phosphatas
jackson
immunoresearch
experi
elisa
plate
coat
follow
mixtur
antigen
yeast
express
didii
diii
e
protein
gener
previous
describ
see
supplementari
experiment
procedur
oliph
et
al
sukupolvipetti
et
al
yeast
cell
express
wild
type
mutant
didii
diii
denv
wnv
strain
new
york
e
protein
stain
mab
ice
min
cell
incub
goat
antihuman
igg
conjug
jackson
immunoresearch
min
ice
analyz
flow
cytometri
equal
amount
concentr
supernat
uninfect
vero
cell
separ
nonreduc
condit
sdspage
transfer
onto
nitrocellulos
membran
filter
block
dri
skim
milk
probe
mab
blot
incub
horseradish
peroxidaseconjug
mous
antihuman
igg
sheep
antimous
igg
donkey
antirabbit
igg
develop
ecl
plu
western
blot
detect
system
ge
healthcar
e
protein
identifi
use
prm
protein
identifi
use
mous
antiprm
mab
falconar
protein
identifi
use
rabbit
serum
young
et
al
c
protein
identifi
band
rna
isol
rneasi
kit
qiagen
ebvimmort
b
cell
clone
cdna
synthes
mmlv
revers
transcriptas
invitrogen
variabl
region
heavychain
lightchain
gene
sequenc
clone
pcr
human
express
vector
provid
nussenzweig
howard
hugh
medic
institut
rockefel
univers
new
york
use
genespecif
primer
pfu
turbo
stratagen
tiller
et
al
vector
contain
murin
ig
gene
signal
peptid
sequenc
multipl
clone
site
upstream
human
constant
region
either
wildtyp
leucinetoalanin
mutat
posit
accord
imgt
uniqu
number
cdomain
lala
mutant
hessel
et
al
introduc
sitedirect
mutagenesi
genscript
equal
amount
heavi
light
chain
vector
mix
equal
amount
polyethylenimin
sigma
incub
min
ad
confluent
cell
atcc
dmem
supplement
nutridoma
roch
antibodi
recov
supernat
harvest
day
transfect
purifi
use
protein
affin
chromatographi
follow
sephadex
sizeexclus
chromatographi
denv
neutral
measur
use
flow
base
assay
day
infect
vero
cell
plate
flatbottom
plate
differ
dilut
mab
mix
denv
moi
ad
vero
cell
three
day
cell
fix
formaldehyd
permeabil
pb
fc
saponin
stain
cell
incub
goat
antimous
igg
conjug
rphycoerythrin
southern
biotechnolog
analyz
flow
cytometri
ec
valu
determin
nonlinear
regress
analysi
ade
measur
flow
assay
use
cell
mab
denv
moi
mix
hour
ad
three
day
cell
fix
permeabil
stain
number
infect
cell
determin
flow
cytometri
potent
enhanc
antibodi
serum
primari
dengueinfect
donor
mix
equal
volum
lala
cocktail
attenu
viru
strain
moi
antibodi
mix
ad
cell
incub
three
day
cell
stain
analyz
flow
cytometri
describ
mice
lack
interferon
receptor
van
den
broek
et
al
bred
univers
california
berkeley
anim
facil
experiment
procedur
preapprov
univers
california
berkeley
anim
care
use
committe
acuc
perform
accord
guidelin
uc
berkeley
acuc
mice
inject
ip
mab
pb
antidenv
sera
total
volum
infect
hour
later
either
pfu
denv
strain
dilut
volum
intraven
iv
inject
tail
vein
experi
mab
transfer
mice
iv
hour
postinfect
assess
therapeut
efficaci
mab
mortal
data
express
use
kaplanmei
surviv
curv
logrank
analys
use
determin
statist
signific
use
prism
graphpad
softwar
viral
load
valu
differ
tissu
compar
experiment
group
use
twosampl
wilcoxon
ranksum
analysi
stata
colleg
station
texa
refer
web
version
pubm
central
supplementari
materi
elisa
concentr
supernat
uninfect
control
vero
cell
separ
nonreduc
condit
b
eand
capsidspecif
mab
e
protein
identifi
mab
specif
e
protein
elisa
capsid
migrat
appar
molecular
weight
kd
c
show
prmspecif
mab
prm
protein
identifi
mous
antiprm
mab
show
mab
protein
identifi
rabbit
serum
data
repres
least
two
independ
experi
e
exampl
viral
neutral
assay
serial
dilut
mab
incub
addit
vero
cell
shown
percentag
infect
cell
day
function
increas
mab
concentr
nonlinear
regress
analysi
use
calcul
ec
valu
indic
panel
f
infect
enhanc
assay
serial
mab
dilut
incub
addit
cell
shown
percentag
infect
cell
rang
mab
concentr
infect
enhanc
observ
indic
gray
number
gray
area
repres
logarithm
power
data
shown
one
repres
experi
three
independ
experi
perform
data
obtain
panel
denvreact
mab
shown
tabl
three
mab
select
specif
neutral
activ
bind
diii
bind
didii
crossreact
didii
denv
serotyp
neutral
enhanc
infect
recombin
unmodifi
mab
b
neutral
enhanc
infect
engin
lala
variant
mab
nonlinear
regress
analysi
use
calcul
ec
indic
panel
data
mean
duplic
one
repres
experi
three
perform
c
cocktail
lalamab
use
combin
mab
direct
prm
didii
e
protein
serum
primari
denvinfect
donor
potent
enhanc
concentr
cell
number
quadrant
indic
percentag
infect
cell
reveal
stain
anti
mous
mab
data
shown
one
experi
repres
two
perform
see
also
figur
tabl
mice
infect
h
later
pfu
strain
bottom
mg
lala
variant
pb
transfer
ip
volum
mice
per
group
mice
subsequ
infect
h
later
pfu
mice
receiv
lalavari
mab
surviv
compar
mice
receiv
lethal
antibodyenhanc
infect
lala
p
lala
p
compar
mab
posit
control
b
mice
administ
serum
ip
infect
h
later
pfu
iv
twentyfour
h
infect
mice
treat
either
lala
lala
lala
pb
ip
case
mortal
monitor
daili
ten
day
mice
treat
either
lala
p
lala
p
h
postinfect
surviv
significantli
longer
mice
receiv
nonbind
lala
variant
mab
see
also
figur
figur
data
shown
repres
two
independ
experi
nd
done
od
valu
od
valu
neutral
highest
concentr
test
tabl
report
phenotyp
didiiand
especif
mab
donor
mab
isol
mab
isotyp
light
chain
usag
determin
specif
elisa
target
specif
mab
determin
elisa
perform
recombin
e
protein
serotyp
diii
stain
yeast
express
di
dii
diii
e
protein
four
mab
recogn
e
protein
elisa
bound
e
protein
western
blot
shown
ec
valu
rang
mab
concentr
infect
enhanc
observ
tabl
data
shown
repres
two
independ
experi
nd
done
od
valu
od
valu
neutral
highest
concentr
test
see
also
tabl
character
nonereact
mab
tabl
report
phenotyp
nonereact
mab
donor
mab
isol
mab
isotyp
light
chain
usag
determin
specif
elisa
specif
determin
stain
vero
cell
infect
denv
western
blot
assay
elisa
specif
mab
assign
na
mab
isotyp
light
chain
usag
determin
describ
tabl
viral
neutral
enhanc
assay
perform
vero
cell
respect
use
vaccin
strain
shown
ec
valu
neutral
rang
mab
concentr
infect
enhanc
data
shown
repres
two
independ
experi
